> CLINICAL RESULTS
After 28 days of application of Atoderm Palmakera daily the product:
Significantly reduces epidermal thickness (-22%) *and skin roughness (-32,9 %)* (1)- Significantly reduces 73%* desquamations, showing a better cohesion of the corneocytes of the stratum corneum (2)
- Significantly increases the rate of cutaneous hydration by +86,0%* in 2h. This hydrating effect persists 24 hours after application with an increase in hydration of +28,9 %*(3)
- Significant decrease in Insensible Water Loss by 23%*(4)
- After the application of Atoderm Palmakera, a significant reduction of redness (-63%****) (5) compared to placebo is observed, indicating that the product limits the appearance of redness.
> ACTION ON PAIN
Atoderm Palmakera reduces the pain felt by patients. More than 85% of patients thought that Atoderm Palmakera relieves the sensations of overheating (6) and smoothes the skin(7).
This is achieved through the action of AntalgicineTM, a synthetic biomimetic lipopeptide. This dipeptide is the acetylated form of a peptide naturally present in the body: Kyotorphine, which interferes with the perception of pain.
Kyotorphine has its own cellular receptors which activate an incoming calcium flow (IP3 gate) and cause a release of Met-enkephalin, thus inhibiting pain.
In addition, in vitro studies on keratynocytes have shown that the addition of Antalgicine stimulates the synthesis of POMC, a precursor of endorphins and enkephalins.
> ZOOM ON CANCER PATIENTS
In patients treated with chemotherapies (+/-radiotherapy):
After 56 days of use of Atoderm Palmakera, as often as necessery, the investigator judged Atoderm Palmakera to be effective to very effective in 97.4% of cases in prevention of grade 1 Hand-Foot Syndrome (HFS), according to the CTCAE v5.0 classification. (8)
> ZOOM ON DIABETIC SUBJECTS
In patients with dry feet without alteration of the sensitivity, Atoderm Palmakera applied at least once a day, showed a statistically significant decrease in the degree of dryness (-30%)***(7) and desquamation (-28%) **(7).
> TOLERANCE
The tolerance of Atoderm Palmakera was evaluated very good in patients under chemotherapy and diabetics (7,8)
*(p<0.05, Student's t test), after 24 hours or 28 days, 3 =1
** (p =0,.039 Wilcoxon test), after 28 days 4=2
***(p <0.001 Wilcoxon test), at D28 1=3
****(p<0,0001, Anova Test), before and after application for 18 hours 2=4
> PATIENTS FEEDBACKS
The product was pleasant for all subjects.(8)
More than 90% of the subjects appreciated its scent and ability to penetrate.(8)
Patients have found that their skin is nourished and strengthened around the nails.(8)
(1)Evaluation of Atoderm Palmakera efficacy in reducing epidermal thickness and skin roughness – 22 volunteers (aged 43-71 years old) with a daily application. France. 2019
(2)Evaluation of Atoderm Palmakera in efficacy in reduction of desquamations showing a better cohesion of the stratum corneum dry, very dry to rough skin on the heel – 23 volunteers (aged 60 years old). France
(3)Evaluation of cutation hydration rate by corneometric of Atoderm Palmakera – 10 volunteers (aged 29 to 69 years old), with dry or moderately moisturized skin on the inside of the forearms with only one application. France. 2018
(4)Evaluation of the effect on reconstruction by measuring insensible water loss with dry and unstructured skin on the forearms – 12 volunteers (aged 24 to 60 years old). France. 2019
(5)Biometrological evaluation of the soothing and anti-redness effect of Atoderm Palmakera – 20 subjects with phototype I to IV, without reactive and/or sensitive skin. France. 2019
(6)User test on Atoderm Palmakera with dry to very dry skin on the hands and feet. France 2019 – 117 volunteers (aged 18-69 years old). France. 2019
(7)Efficacy and tolerance assessment of Atoderm Palmakera on diabetic foot with application at least once a day – 30 subjects (aged 39 to 75 years old). Maurititus. 2019
(8)Evaluation and tolerance assessment of Atoderm Palmakera on hand foot syndrome with application at least once a day - 42 subjects (aged 32 to 62 years old). Georgia. 2019/2020
